Published in Cancer Weekly, December 12th, 2006
For the nine months, the company reported a net loss from continuing operations of $8.0 million, or $0.10 (US$0.09) per share, compared to a net loss from continuing operations of $23.2 million, or $0.32 (US$0.29) per share, for the same period in 2005. The company had cash and cash...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.